Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetamide SCHEMBL10381592 | 0.85 | EPHX1 (0.62) | EPHX1LMNAPOLBALDH1A1KMT2A | |
| SCHEMBL409221 | 0.83 | EPHX1 (0.80) | EPHX1LMNAPOLBALDH1A1HPGD | |
| SCHEMBL4626384 | 0.83 | EPHX1 (0.80) | EPHX1LMNAPOLBALDH1A1HPGD | |
| SCHEMBL538474 | 0.83 | EPHX1 (0.80) | EPHX1LMNAPOLBALDH1A1HPGD | |
| SCHEMBL20440346 | 0.83 | EPHX1 (0.80) | EPHX1LMNAPOLBALDH1A1HPGD | |
| SCHEMBL5515259 | 0.83 | EPHX1 (0.80) | EPHX1LMNAPOLBALDH1A1HPGD | |
| SCHEMBL18825665 | 0.83 | EPHX1 (0.80) | EPHX1LMNAPOLBALDH1A1HPGD | |
| SCHEMBL13423666 | 0.83 | EPHX1 (0.80) | EPHX1LMNAPOLBALDH1A1HPGD | |
| Methoxymethane SCHEMBL28360294 | 0.81 | EPHX1 (0.71) | EPHX1LMNAPOLBALDH1A1HPGD | |
| Methoxymethane SCHEMBL28364135 | 0.81 | EPHX1 (0.71) | EPHX1LMNAPOLBALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812331-B2 | BACTERICIDES | AVENTIS PHARMA S.A. (FR) | 2004-11-02 | — | — | US | disclosed |
| US-6350733-B1 | 4-HYDROXYBENZOPYRAN-2-ONE DERIVATIVES; BACTERICIDES FOR STAPHYLOCOCCUS INFECTIONS; SKIN DISORDERS | AVENTIS PHARMA S.A. (FR) | 2002-02-26 | — | — | US | disclosed |
| US-20020010322-A1 | New aromatic derivatives substituted by a ribose, their preparation process and their use as medicaments | AVENTIS PHARMA S.A. | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010322-A1 | New aromatic derivatives substituted by a ribose, their preparation process and their use as medicaments | RPIA, CD38, PARP1 | EPHX1 3849/4885LMNA 1772/4885POLB 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.